TWiV 840: COVID-19 clinical update #92 with Dr. Daniel Griffin
About this episode
In COVID-19 clinical update #92, Dr. Griffin reviews emerging data on the Omicron variant, much information about monoclonal antibody treatment, including expansion of EUA for Lilly's cocktail, FDA EUA for pre-exposure prophylaxis, outcomes after treatment, and investigation of subcutaneous or intramuscular administration; effect of adding immunomodulatory agents to usual care on thromboembolic events, and long COVID following infection in previously vaccinated individuals.
Hosts: Daniel Griffin and Vincent Racaniello
Subscribe (free): iTunes, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode
- Risk associated with Omicron (medRxiv)
- Expansion of monoclonal EUA (FDA)
- Neutralization of Omicron by sera (medRxiv)
- Third dose sera neutralize Omicron (Pfizer)
- Monoclonals authorized for PreP (FDA)
- Patient outcomes after monoclonals (Open Forum Inf Dis)
- Subcutaneous or intramuscular monoclonals (medRxiv)
- WHO does not recommend convalescent serum (WHO)
- Immunomodulation and thromboembolic risk (J Clin Med)
- Long COVID after infection of vaccinated (medRxiv)
- Letters read on TWiV 840
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees
Send your questions for Dr. Griffin to [email protected]
Get every episode summarized
Each time This Week in Virology publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from This Week in Virology
TWiV 1309: Maybe they're all cancer vaccines
This Week in Virology
TWiV 1308: Clinical update with Dr. Daniel Griffin
This Week in Virology
TWiV 1307: My heart breaks for flu
This Week in Virology
TWiV 1306: Clinical update with Dr. Daniel Griffin
This Week in Virology